argenx

Together We Discover

Third Quarter 2023 Financial Results and Business Update

October 31, 2023

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company's own internal estimates and research. While argenx believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of argenx's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

The contents of this presentation include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "hope," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements argenx makes regarding its launch of VYVGART for generalized myasthenia gravis (gMG) and expansion strategy to reach more patients with VYVGART through additional regulatory approvals; the safety profile and efficacy of VYVGART, the advancement of ARGX-117 and ARGX-119 to clinical proof-of-concept; the planned SC approval and June 20th PDUFA date; its ability to transform gMG treatment for patients; its anticipated clinical data readouts, including in chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), pemphigus vulgaris (PV), postural orthostatic tachycardia syndrome (POTS) and multifocal motor neuropathy (MMN); the therapeutic potential and patient treatment experience of its product candidates, its strategy to expand access to treatments through engagement with physicians, payors, and patient communities; expected filing of the sBLA for VYVGART Hytrulo in CIDP by the end of 2023; pending regulatory reviews of SC efgartigimod for gMG in China, Canada, Europe, and Japan; expectations about its pipeline progress; its collaborations and their potential benefits; the intended results of its strategy and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing of planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals; and its 2023 business and financial outlook and related plans. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including the effects of the COVID-19 pandemic, inflation and deflation and the corresponding fluctuations in interest rates; regional instability and conflicts, such as the conflict between Russia and Ukraine, argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Driving Sustained Growth Across the Business

Consistent Execution + Perpetual Innovation



Double-digit growth quarter over quarter	Approval in Canada	Filing of CIDP sBLA by EOY	GO decision in MMN

What FcRn Leadership Looks Like Today

20 presentations demonstrating neuromuscular leadership

AANEM
American Association of Neuromuscular & Electrodiagnostic Medicine

mg
MYASTHENIA GRAVIS FOUNDATION OF AMERICA
For a World Without Myasthenia Gravis

>1,000 Patient Years

of safety data across indications

Real-world experience in **~6,000 patients**

Favorable Safety

TEAEs mild to moderate

Consistent Efficacy

MG-ADL, QMG, QoL, MSE

Deep FcRn Expertise

Unique target modulation

argenx

ITP ADVANCE-SC Trial

Adult Chronic or Persistent ITP patients

2 weeks screening

Mean platelet count <30x10^9/L

Stable concomitant ITP therapy allowed

Stratification: splenectomy, concomitant ITP therapy



Primary endpoint: Sustained platelet count (≥50×10^9/L) in ≥4/6 visits between weeks 19 and 24

Stringent endpoint in line with regulatory feedback, addressing platelet count variability

Secondary and exploratory endpoints center around extent of disease control to illustrate real-world viability

Topline data expected **4Q 2023**

q2w = every other week

Pemphigus ADDRESS Trial

address
pemphigus study

Screening

Pemphigus vulgaris (PV) and foliaceus (PF)

Moderate-to-Severe Disease (PDAI activity score ≥ 15)

Newly Diagnosed and Relapsing

1-3 weeks

Concomitant prednisone

Prednisone starting dose 0.5 mg/kg/day with ability to adjust

Active tapering to start from sustained CR or EoC

Randomization (2x1)

30 weeks

Primary endpoint is proportion of PV patients achieving CRmin* within 30 weeks

N=222 (PV and PF)
PF patients capped

Followed by Open Label Extension study

Topline data expected around YE 2023

argenx

CR=complete clinical remission; CRmin=complete remission on minimal therapy; EoC=end of consolidation; SC=subcutaneous.

Steady Cadence of **Upcoming Data Readouts**

clinical

advance	ITP-SC: Topline data expected in 4Q 2023
address	Pemphigus: Topline data expected around year-end 2023
ballad	Bullous Pemphigoid (BP): GO/NO GO decision expected around year-end 2023
alpha	Post-COVID Postural Orthostatic Tachycardia Syndrome (PC-POTS): Topline data expected in 1Q 2024
rho STUDY	Sjogren's Syndrome: Topline data expected in first half 2024
alkivia	Myositis: GO/NO GO decision expected in second half of 2024
arda	Multifocal Motor Neuropathy (MMN): Topline data from Phase 2 (empasiprubart) expected in 2024

Third Quarter 2023 Finance Summary

Q3 2023 Product Net Sales of $329M



Product Net Sales by Region

(in millions of $)	Q3 2023	Q2 2023	QoQ % Growth
US	280	244	+15%
Japan	15	13	+15%
EMEA	26	12	+128%
China	7	-	n/a
Total	**329**	**269**	**+22%**

Table in $'m and impacted by rounding.

Summary P/L

(in millions of $)	Three months ended September 30		Nine months ended September 30	
	2023	2022	2023	2022
Product net sales	329	131	816	227
Other & collaboration rev	11	15	34	36
Total operating income	340	146	851	263
Total operating expenses	(420)	(355)	(1,137)	(869)
Operating loss for the period	(81)	(209)	(286)	(606)
Financial inc / (exp)	(3)	(32)	43	(82)
Loss before tax	(83)	(241)	(243)	(688)
Tax	11	6	47	17
Loss for the period	(73)	(235)	(196)	(671)

Total Operating Expenses include Cost of Sales, R&D, SG&A and Loss from investment in joint venture.
Financial income / (expenses) includes financial income / (expenses) and exchange gains / (losses).
Table in $'m and impacted by rounding.

Ended third quarter 2023 with cash of $3.2B

Cash reflects cash, cash equivalents and current financial assets.

Multi-dimensional Expansion to Reach Autoimmune Patients Globally



Optimizing Core Launch Strategies

Hytrulo launch driven by VYVGART-naïve patients

Reaching Broader gMG Population

Hytrulo contributing to expansion

Continued shift into earlier lines

$816M

IN COMBINED NET VYVGART & HYTRULO SALES YTD

Driving brand loyalty among prescribers

88% of key target prescribers reached since launch

First Hytrulo policies published

Policies in line with IV

Innovating on the Patient Experience

Future product presentations providing flexibility in HOW and WHERE patients are treated

Today

1

VYVGART® Hytrulo

(efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

- Single 30-90 second Injection
- Effective
- Safe

Future

2 **Second Generation**

- Pre-filled Syringe (PFS)
- Ongoing development in BE/HF studies
- Aim to support self-administration[1]

More details early next year

3 **Future Generations**

- Exclusive collaboration Halozyme
- Collaboration on formulation elektrofi
- Exploring autoinjector and additional formats to optimize patient experience

Note: Self administration expected on label in Europe and Japan

Reaching gMG Patients Across the Globe



VYVGART®

APPROVALS COMPLETE	
U.S.	DEC 2021
JAPAN	JAN 2022
EUROPE	SEPT 2022
UK	MAR 2023
ISRAEL	APRIL 2023
CHINA	JUNE 2023
CANADA	SEPT 2023

VYVGART® Hytrulo

APPROVALS COMPLETE	
U.S.	JUNE 2023

APPROVALS PENDING	
JAPAN	BY Q1 2024
EUROPE	Q4 2023
CHINA	2024

argenx

Advancing Hytrulo in CIDP

adhere
chronic inflammatory demyelinating polyneuropathy study

First Innovation in 30+ Years

Potential new treatment modality

Bringing Hope to Patients of New Treatment Option

99% rollover into OLE

Crystal
Living With CIDP

I was the type of woman that would run first thing in the morning before work, and then CIDP hit, and it was like hitting the wall at a hundred miles an hour.

Unlocking New Disease Biology Insights

IgG shown to play **significant role** in underlying biology of CIDP

Largest Global CIDP Trial

New standard set for innovative trial design

On track to file sBLA in 2023 with launch targeted in 2024

argenx

Our mission continues…